Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rovalpituzumab Tesirine in Japanese Patients with Advanced SCLC
NCT03086239Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2017
- Primary completion
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of rovalpituzumab tesirine in small cell lung cancer (SCLC) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Dose-Limiting Toxicities at 3 weeks. Started Apr 2017; status: completed.
02
Drugs
rovalpituzumab tesirine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03086239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086239.